[Skip to Content]
[Skip to Content Landing]
Comment & Response
December 2015

Time-Dependent Measurement of Adverse Events

Author Affiliations
  • 1Department of Dermatology, Westmead Hospital, Sydney, Australia
  • 2Sydney Medical School, The University of Sydney, Sydney, Australia
  • 3Research and Education Network, Westmead Hospital, Sydney, Australia

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2015;151(12):1392. doi:10.1001/jamadermatol.2015.3579

To the Editor Recently, anti–programmed cell death protein 1 drugs have shown durable response in melanoma, non–small-cell lung cancers, and renal cell cancers.1,2 The article “Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression” by Sanlorenzo et al3 describes interesting clinical findings, yet we have the following comments regarding the statistical analyses.